Fortress Biotech, Inc., a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, announced that Columbia University (Columbia) has filed a provisional patent application with the US Patent and Trademark Office (USPTO) pertaining to CAEL-101, which was licensed from Columbia to Fortress subsidiary Caelum Biosciences (Caelum) in January 2017.
The patent application, once converted into a US non-provisional, utility application, will provide composition of matter protection for CAEL-101, effective upon a grant of a US patent. The legal protection offered by a granted US patent will exceed any data exclusivity periods associated with Orphan Drug Designation and/or an original, branded biologic product approved for marketing in the US. Caelum also plans to pursue an international (PCT) application, from which national stage patent applications can be submitted in both industrial jurisdictions and developing countries around the world.
A provisional patent application offers a patent applicant an option of filing without including a formal patent claim. In Columbia’s case, however, numerous patent claims have been included in the provisional application, as filed, which are directed to an antibody, which is CAEL-101, pharmaceutical compositions comprising same, methods of treatment, production and detection, as well as vector constructs, polypeptides and polynucleotides. The aim of a provisional patent application is to establish an early effective filing date, in addition to allowing the patent applicant or a licensee to ascribe the phrase “patent pending” to any commercial products, methods, or services contemplated by the subject matter claimed.
Caelum Biosciences, Inc., a Fortress Biotech company, is a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases.
Fortress biotech announces filing, provisional patent application, caelum biosciences
8.jpg)
